^
Association details:
| Biomarker: | Chr amplification(1)(q21) |
|---|---|
| Cancer: | Multiple Myeloma |
| Regimen: | (lenalidomide + Sarclisa (isatuximab-irfc) + carfilzomib + dexamethasone injection) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
UPDATED INTERIM ANALYSIS OF THE GMMG-CONCEPT TRIAL INVESTIGATING ISATUXIMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA-KRD) IN FRONT-LINE TREATMENT OF HIGH-RISK MULTIPLE MYELOMA
Published date:
05/12/2021
Excerpt:
HR MM is defined by the presence of del17p or t(4;14) or t(14;16) or > 3 copies 1q21 in combination with ISS II or III stage disease….updated IA analysis was performed with a median follow-up of 24.9 months. For the overall population analysed, 12- and 24-month PFS (95%>confidence level) was 79.6% (68.3%; 90.9%) and 75.5% (63.5%; 87.6%).
Trial ID:
